BLCO Stock Forecast & Price Target

Bausch & Lomb has demonstrated impressive revenue growth across all three segments in its most recent quarter, with Vision Care achieving $736 million and an 8% year-over-year increase, Surgical revenue at $215 million with a 4% rise, and Pharmaceuticals generating $330 million, also reflecting an 8% growth. The company has regained momentum in premium intraocular lenses and is seeing exceptional prescription growth from its product MIEBO, which achieved a remarkable 110% year-over-year increase in the third quarter of 2025. Additionally, management noted a positive revenue growth of 6% on a constant currency basis, supported by favorable foreign exchange impacts, and the company is maintaining its guidance for 2025, while improving its overall financial performance with a lower-than-expected net loss.

Bausch & Lomb faces significant challenges in maintaining its leadership position in the competitive ophthalmology market, with limited product pipeline investment during its time as a subsidiary of Bausch Health, which may hinder growth prospects. Macroeconomic uncertainties, particularly regarding discretionary spending and elective procedures, add further pressure on its core segments, including contact lenses and surgical offerings. Additionally, the company's high leverage following the acquisition of Xiidra and ongoing uncertainties related to its separation from Bausch Health may restrict financial flexibility and create volatility, reinforcing a negative outlook on the stock.